Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2016 - 2023)

Avalo Therapeutics filings provide 6 years of Long-Term Debt Repayments readings, the most recent being $6.0 million for Q2 2023.

On a quarterly basis, Long-Term Debt Repayments fell 60.0% to $6.0 million in Q2 2023 year-over-year; TTM through Dec 2024 was $6.0 million, a 3.13% decrease, with the full-year FY2023 number at $21.2 million, changed N/A from a year prior.
Long-Term Debt Repayments hit $6.0 million in Q2 2023 for Avalo Therapeutics, up from -$14.8 million in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $15.0 million in Q2 2022 to a low of -$14.8 million in Q4 2022.
Median Long-Term Debt Repayments over the past 3 years was $24342.0 (2019), compared with a mean of $921448.6.
The widest YoY moves for Long-Term Debt Repayments: up 60.0% in 2023, down 60.0% in 2023.
Avalo Therapeutics' Long-Term Debt Repayments stood at $183114.0 in 2019, then crashed by 8185.67% to -$14.8 million in 2022, then soared by 140.52% to $6.0 million in 2023.
The last three reported values for Long-Term Debt Repayments were $6.0 million (Q2 2023), -$14.8 million (Q4 2022), and $15.0 million (Q2 2022) per Business Quant data.